BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6272 related articles for article (PubMed ID: 18047501)

  • 21. Headache prevention outcome and body mass index.
    Bigal ME; Gironda M; Tepper SJ; Feleppa M; Rapoport AM; Sheftell FD; Lipton RB
    Cephalalgia; 2006 Apr; 26(4):445-50. PubMed ID: 16556246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.
    Lowe NJ; Glaser DA; Eadie N; Daggett S; Kowalski JW; Lai PY;
    J Am Acad Dermatol; 2007 Apr; 56(4):604-11. PubMed ID: 17306417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
    Riff DS; Duckor S; Gottlieb I; Diamond E; Soulier S; Raymond G; Boesing SE
    Clin Ther; 2009 Oct; 31(10):2072-85. PubMed ID: 19922878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study.
    Harden RN; Cottrill J; Gagnon CM; Smitherman TA; Weinland SR; Tann B; Joseph P; Lee TS; Houle TT
    Headache; 2009 May; 49(5):732-43. PubMed ID: 19178577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin in migraine prophylaxis.
    Göbel H
    J Neurol; 2004 Feb; 251 Suppl 1():I8-11. PubMed ID: 14991336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin type A for the treatment of nummular headache: four case studies.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2008 Mar; 48(3):442-7. PubMed ID: 18028377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases.
    Tepper SJ; Bigal ME; Sheftell FD; Rapoport AM
    Headache; 2004 Sep; 44(8):794-800. PubMed ID: 15330826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
    Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
    Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.
    Tepper SJ; Cady R; Dodick D; Freitag FG; Hutchinson SL; Twomey C; Kuhn TA
    Headache; 2006 Jan; 46(1):115-24. PubMed ID: 16412159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH; O'Carroll P; Blumenfeld A; DeGryse R; Dimitrova R;
    J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
    Yablon SA; Brashear A; Gordon MF; Elovic EP; Turkel CC; Daggett S; Liu J; Brin MF
    Clin Ther; 2007 Apr; 29(4):683-90. PubMed ID: 17617291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
    Brandes JL; Visser WH; Farmer MV; Schuhl AL; Malbecq W; Vrijens F; Lines CR; Reines SA;
    Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
    Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
    Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
    Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 314.